Showing results (1701-1710 of 2,464) with videos related to
Sort By:
Pageof 247
Journal of Medicinal Chemistry|November 23, 2011
Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptorFrancesca Deflorian, T Santhosh Kumar, Khai Phan, et al.The Journal of Infectious Diseases|June 1, 1989
Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidineM A Jacobson, D I Abrams, P A Volberding, et al.Neurochemistry International|July 24, 1998
Apoptosis by 2-chloro-2'-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cellsD Barbieri, M P Abbracchio, S Salvioli, et al.Journal of Medicinal Chemistry|September 3, 1993
Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptorsK A Jacobson, D Shi, C Gallo-Rodriguez, et al.Journal of Medicinal Chemistry|September 20, 2002
Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundaryZhan-Guo Gao, Soo-Kyung Kim, Thibaud Biadatti, et al.The Journal of Infectious Diseases|April 20, 2011
Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapyPeter W Hunt, Jeffrey N Martin, Elizabeth Sinclair, et al.Transplantation|November 19, 2010
Single-nucleotide polymorphisms, acute rejection, and severity of tubulitis in kidney transplantation, accounting for center-to-center variationAjay Israni, Robert Leduc, John Holmes, et al.Pharmacogenomics|June 13, 2015
Multigene predictors of tacrolimus exposure in kidney transplant recipientsRebecca A Pulk, David S Schladt, William S Oetting, et al.Journal of Clinical Lipidology|June 9, 2020
Genetic testing in dyslipidemia: A scientific statement from the National Lipid AssociationEmily E Brown, Amy C Sturm, Marina Cuchel, et al.The Journal of Infectious Diseases|April 11, 2001
Cytomegalovirus (CMV)-specific CD4+ T lymphocyte immune function in long-term survivors of AIDS-related CMV end-organ disease who are receiving potent antiretroviral therapyM A Jacobson, R Schrier, J M McCune, et al.Pageof 247